Introduction
============

The interaction between alpha- and beta-islet cells is responsible for plasma glucose homeostasis.[@b1-dmso-2-203] Predominance of the former and the latter are responsible for hyperglycemia[@b2-dmso-2-203]--[@b4-dmso-2-203] and hypoglycemia,[@b4-dmso-2-203],[@b5-dmso-2-203] respectively. In addition, this binomial peripheral crosstalk is modulated by several physiological factors which include both peripheral neuroendocrine and central nervous system (CNS) mechanisms.[@b6-dmso-2-203],[@b7-dmso-2-203] However, this physiological stability can be disrupted by many stressor factors such as exercise and restraint,[@b8-dmso-2-203],[@b9-dmso-2-203] neuropharmacological agents such as tianeptine (enhancer of serotonin uptake),[@b10-dmso-2-203] doxepin (inhibitor of serotonin uptake),[@b11-dmso-2-203] or dopaminergic-blocking agents (such as sulpiride, haloperidol).[@b12-dmso-2-203],[@b13-dmso-2-203] Quantitative and/or qualitative changes of the above factors might lead to hyper- or hypoglycemic disorders. Most research work dealing with this issue has investiged the peripheral mechanisms involved in the alpha-cell versus beta-cell crosstalk (endocrine, gastrointestinal, and neuroautonomic); however, little research work has been devoted to the understanding of the CNS circuitry responsible for the alpha- versus beta-cells interaction and/or CNS versus peripheral autonomic nervous system (ANS) parameters. The investigation of such crosstalk might redound in findings able to lead to the outlining of adequate neuropharmacological therapeutical strategies addressed to normalize the peripheral disorders responsible for the alpha-cells ↔ beta-cells imbalance.

Evidence have demonstrated that insulin excites neural sympathetic activity[@b14-dmso-2-203],[@b15-dmso-2-203] while glucagon excites adrenal sympathetic activity.[@b16-dmso-2-203]--[@b18-dmso-2-203] In addition, both sympathetic branches of the peripheral ANS depend on the A~5~ pontomedullary nucleus that releases noradrenaline (NA)[@b19-dmso-2-203] and the C~1~ medullary nuclei which secrete adrenaline (Ad).[@b20-dmso-2-203]--[@b24-dmso-2-203] Furthermore, both CNS nuclei interchange direct inhibitory axons whose neurotransmitters act at post-synaptic alpha-2 receptors, which crowd both nuclei.[@b18-dmso-2-203]--[@b25-dmso-2-203] Finally, experimental evidence has demonstrated that secretion of both peripheral hormones (insulin and glucagon) would depend on the interaction between two opposite neuroendocrine circuits. According to the above, we decided to investigate the effect of amantadine, a glutamic acid (N-methyl-D-aspartate \[NMDA\]) antagonist, which inhibits the C~1~ (Ad) but not the A~5~ (NA) nuclei, and provokes absolute reduction of plasma adrenaline concentration when administered to normal subjects during fasting conditions.[@b26-dmso-2-203]--[@b31-dmso-2-203]

Methods
=======

One oral glucose tolerance test (OGTT) plus placebo and one OGTT plus oral amantadine (100 mg) test were carried out two weeks apart in 15 caucasic normal voluntary humans (seven males and eight females), whose ages ranged from 25 to 58 years (mean ± standard error of mean \[SEM\] = 38.4 ± 7.2) ([Tables 1](#t1-dmso-2-203){ref-type="table"}--[3](#t3-dmso-2-203){ref-type="table"}). The study was conducted in accordance with the guidelines in the Declaration of Helsinki. Written informed consent was obtained after the purpose, nature and potential risks had been explained to the subjects. The experimental protocol was approved by the Ethical Committee of FUNDAIME. All subjects were within 10% of ideal body weight, and none had undergone abdominal surgery or were taking any medications. None of the subjects had physical or psychiatric illness. Subjects were rated on a modified Hamilton Depression Rating Scale for depression and all of them completed the self-rating Beck Depression Inventory[@b11-dmso-2-203] in order to discard subjects with depression. Pregnancy, lactation, smoking and/or alcoholism factors also excluded subjects.

Analytical methods
------------------

The assessment of circulating neurotransmitters throughout the OGTT + placebo test carried out according to the present protocol ratified other previously published research studies.[@b10-dmso-2-203],[@b11-dmso-2-203] Noradrenaline, adrenaline, dopamine, plasma free serotonin (f5-HT), platelet serotonin (p5-HT), glucose, glucagon, and insulin were measured throughout the 180-minute testing period. For all parameters, the samples were assayed in duplicate and all determinations were made simultaneously. We used reverse-phase, ion-pair high performance liquid chromatography with electrochemical detection for the detection of monoamines. Optimization of chromatographic conditions and attainment of adequate quantification parameters allowed us to maximize sensitivity and reproducibility.

All tests were performed on recumbent subjects after 14 hours of fasting. A heparinized venous catheter was inserted into a forearm vein at least 30 minutes before beginning the tests. Blood samples were collected at 0, 30, 60, 90, 120, and 180 minutes. Each subject drank a 30% glucose solution (1 g/kg of ideal body weight) plus placebo or an oral dose of amantadine (100 mg = one capsule). Blood for catecholamines and serotonin assays was transferred to plastic tubes, each containing 20 mg of EDTA plus 10 mg of sodium bisulphite/ml of solution. The tubes were carefully inverted and placed on ice. The blood was promptly centrifuged at 600 rpm for 15 minutes at 4°C in order to obtain platelet-rich plasma. Two milliliters of platelet-rich plasma, obtained for determination of platelet serotonin (p5-HT), were taken and stored at −70°C until assayed. The remaining blood was again centrifuged at 7,000 rpm. The supernatant, platelet-poor plasma, was divided into four portions for determination of insulin, glucagon, catecholamines and free serotonin (f5-HT), after which all portions were stored at −70°C until assayed. Plasma glucose samples were immediately processed.

Reagents and standards
----------------------

Noradrenaline, adrenaline, dopamine, serotonin creatinine sulphate, dihydroxybenzylamine, sodium octyl sulphate, dibutylamine, acid-washed aluminium oxide, Na~2~HPO~4~, citric acid and EDTA were purchased from Sigma-Aldrich (St. Louis, MO, USA). Microfilters were purchased from Whatman Inc. (Florham Park, NY, USA) through Merck S.A. (Caracas, Venezuela). Acetonitrile and 2-propanol were obtained from Merck, S.A. Glass-distilled water was de-ionized and filtered through a Milli-Q reagent grade water system (Millipore, Bedford, MA, USA). Solvents were filtered through a 0.2 μm Millipore filter and were vacuum de-aerated. Standard solutions (1 mmo1/L) were prepared in 0.1 mo1/L perchloric acid and diluted to the desired concentration.

Equipment
---------

Liquid chromatography was performed using Waters 515 HPLC pump (Waters Corporation, Milford, MA. USA) equipped with a Rheodyne valve injector 7125i, which was fitted with a 50 μL sample loop (Rheodyne; Berodine, Berkeley, CA, USA). A 15 cm × 4.6 mm inner diameter Discovery C18 column packed with octadecylsilane 5 μm particles was preceded by a column prefilter of 2 μm porosity, both from Supelco/Sigma-Aldrich. The detection system was a Waters 460 Electrochemical Detector (Waters Corporation). The potential of the working electrode (glass carbon) was set at + 0.61 V versus the Ag--AgCl reference electrode for the detection of catecholamines and 0.70 V versus the Ag--AgCl for the detection of indolamines. The chromatograms were registered and quantified with Empower software (Waters Corporation). The results were corrected for the volume of EDTA added.

Analytical assays
-----------------

### Plasma catecholamines

The assay was performed by extraction of the catecholamines onto 20 mg of alumina followed by their elution with 200 μL of 1.0 mo1/L HClO~4~ using regenerated cellulose microfilters 0.2 μm pore size (Whatman Inc.). We calibrated the instrument with standard plasma. After incubation with acid-washed aluminum oxide, a plasma pool of free catecholamines was processed similarly to plasma samples, but 20 μL of a standard solution of noradrenaline, adrenaline, and dopamine (50, 25, and 25 ng/mL, respectively) were added to the plasma pool. Both the standard plasma and the sample plasma were supplemented with 20 μL of internal standard (100 ng/mL of dihydroxybenzylamine). The mobile phase was KH~2~PO~4~ 6.8045 g/L, EDTA 0.100 g/L and di-N-butylamine 100 μl/L. Sodium octyl sulphate was added as ion-pair agent in a concentration of 0.6125 g/L with the pH adjusted to 5.6. The flow rate was 0.400 mL/min. The sensitivity of this method for noradrenaline, adrenaline and dopamine was 6.4, 5.8, and 2.0 pg/mL, respectively. The intraassay coefficients of variation were 2.8%, 4.0%, and 4.0 %, respectively. The inter-assay coefficients of variation were 6.7%, 4.5%, and 4.3%, respectively.

### Plasma indolamines

After sonication of platelet-rich plasma to disrupt the platelets (Ultrasonic Liquid Processor, model 385; Heat Systems Ultrasonics Inc., Farmingdale, NY, USA), both platelet-rich and platelet-poor plasma were processed in the same way: 200 μL of 3.4 mol/L perchloric acid and 50 μl of 5-hydroxy-tryptophan solution (114.5 μg/mL) as internal standard, were added to 1 mL of plasma vortexed and centrifuged at 10,000 rpm for 15 minutes at 4°C. The supernatant was filtered through a 0.22 μm membrane (Millipore) and 10 μL was injected into the column. Calibration runs were generated by spiking blank platelet-poor plasma with 50 μL of a solution containing 5-HT (10 μg/mL) and 50 μL of 5-hydroxy-tryptophan (114.5 μg/mL). This standard plasma was processed in the same manner as the samples. The mobile phase was citric acid 3.8424 g/L, sodium acetate 4.1015 g/L, EDTA 0.100 g/L, di-N-butylamine 100 μl/L, and 30 ml/L of 2-propanol. Sodium octyl sulphate was added as ion-pair agent in a concentration of 4.25 mg/L with a pH of 5.0. The flow rate was 0.610 mL/min. The sensitivity of the method for serotonin was 0.1 ng/mL. The intra-assay coefficients of variation for p5-HT and f5-HT were 6.2% and 8.7%, respectively.

### Plasma insulin

This was determined in duplicate by insulin ELISA kit (Cosmo Bio, Carlsbad, CA, USA).

### Plasma glucagon

Plasma glucagon was determined by radioimmunoassay (RIA) kit GL-32K (Linco Research; Millipore). In our hands, the intraassay variation was 4.5 ± 1.2 and 11.1 ± 2.8 for the interassay variation.

### Plasma glucose

Plasma glucose concentration was measured in duplicate with a glucose oxidase method[@b32-dmso-2-203] using Glucose Analyzer II (Beckman Instruments, Fullerton, CA, USA).

Statistical methods
-------------------

Results are presented as the mean ± SEM. Statistical significance was set at \**P* \< 0.05; \*\**P* \< 0.02; \*\*\**P* \< 0.01 (versus 0 min value). Multivariate ANOVA with repeated measurements, paired t test, and correlation coefficients (exploratory factor analysis) were used. dBase Stats™ (Ashton Tate, Chicago, IL, USA) and StatView SE + Graphics (SAS Institute, Cary, NC, USA) were used for statistical analyses.

Results
=======

Oral glucose + placebo test
---------------------------

Suppression of plasma glucagon concentration was observed throughout the test with a nadir of 40.0 ± 5.0 pg/mL at the 90-minute period. Maximal rise of glucose was registered at the 30-minute period, whereas minimal mean values were reached at the 180-minute period ([Figure 1](#f1-dmso-2-203){ref-type="fig"}). Noradrenaline and platelet serotonin circulating parameters showed significant and sustained rises which paralleled insulin increases and opposed plasma glucose reductions. Significant reduction of adrenaline values were registered throughout the test. Dopamine did not show significant changes ([Figure 2](#f2-dmso-2-203){ref-type="fig"}). In addition to the above, although both noradrenaline and platelet serotonin concentrations were raised after the oral glucose load, the noradrenaline/p5-HT ratio showed significant falls throughout the OGTT ([Figure 3](#f3-dmso-2-203){ref-type="fig"}). No significant f5-HT changes were registered throughout the test. All of our subjects fell asleep and displayed rapid eye movements (REM) during OGTT, especially accentuated at the 90-minute and 180-minute periods.

Oral glucose + amantadine test
------------------------------

Subjects showed drowsiness but not REM sleep throughout the test. Adrenaline showed maximal and sustained decreases throughout the post-amantadine periods. Conversely, significant and sustained noradrenaline plus dopamine rises opposed the adrenaline falls. In addition, abrupt fall of f5-HT and p5-HT parameters were also registered throughout the OGTT + amantadine challenge ([Figure 4](#f4-dmso-2-203){ref-type="fig"}).

Maximal and sustained reductions of both plasma glucose and glucagon were observed. Small and sustained but significant insulin rises were registered throughout post-glucose + amantadine periods ([Figure 1](#f1-dmso-2-203){ref-type="fig"}). Maximal fall of systolic blood pressure and heart rate, were also observed throughout the post-drug + glucose periods.

Discussion
==========

The results obtained from the present study demonstrated that the addition of a small dose of amantadine (100 mg) to the OGTT was able to enhance the insulinogenic plus hypoglycemic effects normally triggered by the ingested sugar. These effects were paralleled by the enhancement of the normal neural sympathetic overactivity, always registered throughout the OGTT as well as by the accentuation of the fall of the adrenaline plus glucagon plasma levels that occurs after an oral glucose load. Both insulin and glucagon cross the blood--brain barrier and excite the A~5~ (NA)[@b14-dmso-2-203],[@b17-dmso-2-203],[@b33-dmso-2-203],[@b34-dmso-2-203] and the C~1~ (Ad)[@b16-dmso-2-203],[@b33-dmso-2-203]--[@b36-dmso-2-203] pontomedullary nuclei, respectively. The former is responsible for the peripheral neural (noradrenergic) sympathetic activity whereas the latter excites adrenal sympathetic glands, which secrete 80% of adrenaline. The fact that glutamatergic axons innervate and excite the C~1~ (Ad) but not the A~5~ (NA) neurons (by acting at NMDA receptors) explains why amantadine (a NMDA antagonist) interferes with the adrenal but not with the neural sympathetic activity. With respect to this, experimental evidences obtained from our laboratory, demonstrated that a small dose of amantadine (administered without glucose) provokes absolute minimization of the adrenaline plasma concentration.[@b24-dmso-2-203],[@b29-dmso-2-203]

In addition to all the above, some other factors should be considered in order to understand the ability by amantadine to annul the glucagon-induced excitatory effect at the CNS C~1~ (Ad) + peripheral adrenal sympathetic axis, which would explain its insulinogenic + hypoglycemic effects. For instance, the drug was able to provoke maximal reduction of both plasma serotonin and platelet serotonin concentration. This circulating indolamine exerts an inhibitory effect at the beta-cell level and in addition is able to excite alpha-cells, which secrete glucagon.[@b37-dmso-2-203]--[@b41-dmso-2-203] Furthermore, plasma serotonin is able to excite the adrenal glands,[@b39-dmso-2-203],[@b42-dmso-2-203] directly. Thus, the reduction of plasma serotonin plus platelet serotonin circulating values registered in the present study should be taken into account in order to understand the hypoglycemic effect triggered by amantadine, when this drug was added to an oral glucose load.

The minimization of the circulating serotonin concentration (plasma serotonin + platelet serotonin) registered in the present study might find an explanation in the overwhelming neural sympathetic over adrenal sympathetic activity triggered by amantadine. It should be remembered that the release of serotonin from the enterochromaffin cells depends on the excitatory parasympathetic drive which should be interfered by the enhancement of the neural sympathetic activity (noradrenaline/adrenaline ratio) registered in this study.[@b40-dmso-2-203],[@b43-dmso-2-203]--[@b48-dmso-2-203] The minimization of the plasma acetylcholine concentration, which competes with serotonin for the platelet uptake, fits well with the maximal reduction of the plasma serotonin values registered during the post amantadine periods. This postulation is in accordance with the maximal fall of systolic blood pressure and heart rate, observed throughout the post-drug periods. Both cardiovascular parameters are positively correlated with the peripheral adrenal sympathetic activity greatly minimized in the present study because of the inhibition by amantadine of the C~1~ (Ad) medullary nuclei.

In addition to the above, it has been shown that other drugs like tianeptine, which also minimizes plasma serotonin concentration is able to enhance plasma insulin secretion.[@b10-dmso-2-203] This fact should be attributed to the direct inhibitory effect exerted by this indolamine at the beta-cell level.

The enhancement of the noradrenaline/adrenaline plasma ratio registered in the present study indicates that the overwhelming neural sympathetic activity annulled the peripheral adrenal sympathetic branch. This peripheral neuroautonomic profile depends on the absolute predominance of the A~5~ (NA) pontomedullary nucleus over the C~1~ (Ad) medullary nuclei.[@b24-dmso-2-203],[@b49-dmso-2-203] The above CNS A~5~ (NA) versus C~1~ (Ad) predominance which redounded in the peripheral neural sympathetic plus beta-cells hyperactivity merits some additional comments. With respect to this, it should be known that sympathetic nerves innervate and excite alpha-cells by acting at alpha-2 receptors but not beta-cells.[@b20-dmso-2-203]--[@b22-dmso-2-203],[@b50-dmso-2-203] However, glucagon released from the former excites beta-cells which send GABA-inhibitory drive to alpha-cells.[@b41-dmso-2-203] In addition to the above, it should be remembered that both adrenaline and glucagon are positively correlated with glucogenolysis and hyperglycemia both of which are absolutely minimized in the present research study.

According to all the above, we postulate that the postprandial hypoglycemic + insulinogenic effects provoked by the addition of a small dose of amantadine to the OGTT depends on peripheral + central nervous system mechanisms. The former should be attributed to the minimization of the inhibitory effect of circulating serotonin (plasma serotonin + platelet serotonin) plus the suppression of the glucogenolytic effect by adrenaline. At the central nervous system the above phenomena would depend on the inhibition of the C~1~ (Ad) medullary nuclei plus the absolute predominance of the A~5~ (NA) nucleus. Both insulin and glucagon cross the blood brain barrier and excite the A~5~ (NA) and the C~1~ (Ad) pontomedullary nuclei, respectively thus, the inhibition of the latter triggered by amantadine provoked the abrupt suppression of the adrenal glands secretion which favored the absolute predominance of the A~5~ (NA) neural sympathetic branch that resulted in the enhancement of insulin/glucagon ratio, registered in this study. This postulation receives definite support from overwhelming evidence quoted in several review articles and books.[@b24-dmso-2-203],[@b29-dmso-2-203],[@b41-dmso-2-203],[@b51-dmso-2-203],[@b52-dmso-2-203]

Summarizing all the above, it is possible to postulate that the hypoglycemic + hypoglucagonemic + insulinogenic effects triggered by the addition of amantadine to an oral glucose load would depend of both peripheral plus central nervous system mechanisms. The former should be associated to the minimization of the alpha-cells + adrenal glands secretion whereas the latter should be associated with the inhibition of the C~1~ (Ad) plus the disinhibition of the A~5~ (NA), responsible for the peripheral adrenal sympathetic and neural sympathetic branches axis, respectively.
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![The addition of an oral dose of amantadine (100 mg) to an oral glucose load potentiated both the glucose and glucagon reductions and increased postprandial insulin levels in 15 normal healthy subjects (seven males and eight females), whose ages ranged from 25 to 58 years (mean ± SEM = 38.4 ± 7.2).\
**Notes:** Values are expressed as mean ± SEM \**P* \< 0.05; \*\**P \<* 0.02 (versus 0 min value).\
**Abbreviation:** SEM, standard error of mean.](dmso-2-203f1){#f1-dmso-2-203}

![The addition of an oral dose of amantadine (100 mg) to an oral glucose load enhanced the normal noradrenaline and dopamine rises, always observed throughout the OGTT + placebo test. Conversely, maximal reduction of adrenaline opposed the former rises.\
**Notes:** N = 15 (seven males and eight females), whose ages ranged from 25 to 58 years (mean ± SEM = 38.4 ± 7.2). Values are expressed as mean ± SEM. \**P \<* 0.05; \*\**P \<* 0.02; \*\*\**P \<* 0.01 (versus 0 min value).\
**Abbreviations:** OGTT, oral glucose tolerance test; SEM, standard error of mean.](dmso-2-203f2){#f2-dmso-2-203}

![The insulin/glucagon ratio as well as the noradrenaline/adrenaline ratio showed paralleled increases throughout the oral glucose tolerance test when 100 mg of oral amantadine was given to 15 normal healthy subjects (seven males and eight females), whose ages ranged from 25 to 58 years (mean ± SEM = 38.4 ± 7.2).\
**Notes:** Values are expressed as mean ± SEM. \**P* \< 0.05; \*\**P* \< 0.02 (versus 0 min value).\
**Abbreviation:** SEM, standard error of mean.](dmso-2-203f3){#f3-dmso-2-203}

![Both platelet serotonin (p5-HT) and plasma serotonin (f5-HT) showed maximal decreases throughout the test when an oral dose of amantadine (100 mg) was added to an oral glucose load. These findings contrast with the significant rises of both parameters observed throughout the oral glucose load + placebo challenge.\
**Notes:** N = 15 (seven males and eight females), whose ages ranged from 25 to 58 years (mean ± SEM = 38.4 ± 7.2). Values are expressed as mean ± SEM. \**P* \< 0.05; \*\*\**P* \< 0.01 (versus 0 min value).\
**Abbreviation:** SEM, standard error of mean.](dmso-2-203f4){#f4-dmso-2-203}

###### 

Correlations found during the oral glucose tolerance + placebo test performed in 15 normal voluntary human (seven males and eight females)

                      Periods                                                                                                                                                                        
  ------------------- --------- ---- --------------------------------------------------- ----------------------------------------------------- ----------------------------------------------------- -----------------------------------------------------
  NA vs Ad            ns        ns   ns                                                  ns                                                    ns                                                    ns
  NA vs DA            ns        ns   0.203[\*](#tfn2-dmso-2-203){ref-type="table-fn"}    0.256[\*](#tfn2-dmso-2-203){ref-type="table-fn"}      0.321[\*\*](#tfn3-dmso-2-203){ref-type="table-fn"}    0.293[\*\*](#tfn3-dmso-2-203){ref-type="table-fn"}
  Ad vs DA            ns        ns   ns                                                  ns                                                    ns                                                    ns
  NA vs glycemia      ns        ns   −0.221[\*](#tfn2-dmso-2-203){ref-type="table-fn"}   −0.325[\*\*](#tfn3-dmso-2-203){ref-type="table-fn"}   −0.442[\*\*](#tfn3-dmso-2-203){ref-type="table-fn"}   −0.456[\*\*](#tfn3-dmso-2-203){ref-type="table-fn"}
  DA vs glycemia      ns        ns   −0.211[\*](#tfn2-dmso-2-203){ref-type="table-fn"}   −0.247[\*](#tfn2-dmso-2-203){ref-type="table-fn"}     −0.354[\*\*](#tfn3-dmso-2-203){ref-type="table-fn"}   −0.376[\*\*](#tfn3-dmso-2-203){ref-type="table-fn"}
  Ad vs glycemia      ns        ns   ns                                                  ns                                                    ns                                                    ns
  NA vs p5-HT         ns        ns   ns                                                  ns                                                    ns                                                    ns
  Ad vs p5-HT         ns        ns   ns                                                  ns                                                    ns                                                    ns
  DA vs p5-HT         ns        ns   ns                                                  ns                                                    ns                                                    ns
  p5-HT vs glycemia   ns        ns   ns                                                  ns                                                    ns                                                    ns
  NA vs insulin       ns        ns   0.325[\*](#tfn2-dmso-2-203){ref-type="table-fn"}    0.411[\*\*](#tfn3-dmso-2-203){ref-type="table-fn"}    0.401[\*\*](#tfn3-dmso-2-203){ref-type="table-fn"}    0.397[\*\*](#tfn3-dmso-2-203){ref-type="table-fn"}
  DA vs insulin       ns        ns   0.214[\*](#tfn2-dmso-2-203){ref-type="table-fn"}    0.222[\*](#tfn2-dmso-2-203){ref-type="table-fn"}      0.216[\*](#tfn2-dmso-2-203){ref-type="table-fn"}      0.217[\*](#tfn2-dmso-2-203){ref-type="table-fn"}
  Ad vs insulin       ns        ns   ns                                                  ns                                                    ns                                                    ns
  p5-HT vs insulin    ns        ns   −0.212[\*](#tfn2-dmso-2-203){ref-type="table-fn"}   −0.223                                                −0.231[\*](#tfn2-dmso-2-203){ref-type="table-fn"}     −0.214[\*](#tfn2-dmso-2-203){ref-type="table-fn"}
  NA vs glucagon      ns        ns   −0.299[\*](#tfn2-dmso-2-203){ref-type="table-fn"}   −0.297[\*](#tfn2-dmso-2-203){ref-type="table-fn"}     −0.365[\*\*](#tfn3-dmso-2-203){ref-type="table-fn"}   −0.377[\*\*](#tfn3-dmso-2-203){ref-type="table-fn"}
  DA vs glucagon      ns        ns   ns                                                  −0.288[\*](#tfn2-dmso-2-203){ref-type="table-fn"}     −0.322[\*](#tfn2-dmso-2-203){ref-type="table-fn"}     −0.315[\*](#tfn2-dmso-2-203){ref-type="table-fn"}
  Ad vs glucagon      ns        ns   ns                                                  ns                                                    ns                                                    ns
  P5-HT vs glucagon   ns        ns   ns                                                  ns                                                    ns                                                    ns
  NA vs HR            ns        ns   ns                                                  ns                                                    ns                                                    ns
  Ad vs HR            ns        ns   ns                                                  ns                                                    ns                                                    ns
  DA vs HR            ns        ns   ns                                                  ns                                                    ns                                                    ns
  NA/Ad vs SBP        ns        ns   ns                                                  ns                                                    ns                                                    ns
  NA/Ad vs DBP        ns        ns   0.207[\*](#tfn2-dmso-2-203){ref-type="table-fn"}    0.214[\*](#tfn2-dmso-2-203){ref-type="table-fn"}      0.221[\*](#tfn2-dmso-2-203){ref-type="table-fn"}      0.218[\*](#tfn2-dmso-2-203){ref-type="table-fn"}
  DA vs SBP           ns        ns   ns                                                  ns                                                    ns                                                    ns
  DA vs DBP           ns        ns   −0.213[\*](#tfn2-dmso-2-203){ref-type="table-fn"}   −0.210[\*](#tfn2-dmso-2-203){ref-type="table-fn"}     −0.220[\*](#tfn2-dmso-2-203){ref-type="table-fn"}     −0.222[\*](#tfn2-dmso-2-203){ref-type="table-fn"}

**Notes:** Levels of significance,

*P* \< 0.05;

*P* \< 0.01.

**Abbreviations:** NA, noradrenaline; Ad, adrenaline; DA, dopamine; p5-HT, platelet serotonin; f5-HT, plasma serotonin; HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure.

###### 

Correlations found during the oral glucose tolerance + amantadine test performed in 15 normal voluntary human (seven males and eight females)

                       Periods                                                                                                                                                                          
  -------------------- --------- ---- ----------------------------------------------------- ----------------------------------------------------- ----------------------------------------------------- -----------------------------------------------------
  NA vs Ad             ns        ns   ns                                                    ns                                                    ns                                                    ns
  NA vs DA             ns        ns   0.368[\*\*](#tfn7-dmso-2-203){ref-type="table-fn"}    0.377[\*\*](#tfn7-dmso-2-203){ref-type="table-fn"}    0.405[\*\*](#tfn7-dmso-2-203){ref-type="table-fn"}    0.426[\*\*](#tfn7-dmso-2-203){ref-type="table-fn"}
  Ad vs DA             ns        ns   ns                                                    ns                                                    ns                                                    ns
  NA vs glycemia       ns        ns   −0.267[\*](#tfn6-dmso-2-203){ref-type="table-fn"}     −0.338[\*\*](#tfn7-dmso-2-203){ref-type="table-fn"}   −0.422[\*\*](#tfn7-dmso-2-203){ref-type="table-fn"}   −0.439[\*\*](#tfn7-dmso-2-203){ref-type="table-fn"}
  DA vs glycemia       ns        ns   −0.332[\*](#tfn6-dmso-2-203){ref-type="table-fn"}     −0.365[\*](#tfn6-dmso-2-203){ref-type="table-fn"}     −0.411[\*\*](#tfn7-dmso-2-203){ref-type="table-fn"}   −0.395[\*\*](#tfn7-dmso-2-203){ref-type="table-fn"}
  Ad vs glycemia       ns        ns   ns                                                    ns                                                    ns                                                    ns
  NA vs p5-HT          ns        ns   −0.244[\*](#tfn6-dmso-2-203){ref-type="table-fn"}     −0.332[\*](#tfn6-dmso-2-203){ref-type="table-fn"}     −0.326[\*](#tfn6-dmso-2-203){ref-type="table-fn"}     −0.299[\*](#tfn6-dmso-2-203){ref-type="table-fn"}
  Ad vs p5-HT          ns        ns   ns                                                    ns                                                    ns                                                    ns
  DA vs p5-HT          ns        ns   −0.237[\*](#tfn6-dmso-2-203){ref-type="table-fn"}     −0.314[\*](#tfn6-dmso-2-203){ref-type="table-fn"}     −0.333[\*](#tfn6-dmso-2-203){ref-type="table-fn"}     ns
  p5--HT vs glycemia   ns        ns   0.244[\*](#tfn6-dmso-2-203){ref-type="table-fn"}      0.338[\*](#tfn6-dmso-2-203){ref-type="table-fn"}      0.352[\*](#tfn6-dmso-2-203){ref-type="table-fn"}      0.341[\*](#tfn6-dmso-2-203){ref-type="table-fn"}
  NA vs insulin        ns        ns   0.211[\*](#tfn6-dmso-2-203){ref-type="table-fn"}      0.253[\*](#tfn6-dmso-2-203){ref-type="table-fn"}      0.324[\*\*](#tfn7-dmso-2-203){ref-type="table-fn"}    0.323[\*\*](#tfn7-dmso-2-203){ref-type="table-fn"}
  DA vs insulin        ns        ns   0.199[\*](#tfn6-dmso-2-203){ref-type="table-fn"}      0.218[\*](#tfn6-dmso-2-203){ref-type="table-fn"}      0.235[\*](#tfn6-dmso-2-203){ref-type="table-fn"}      0.239[\*](#tfn6-dmso-2-203){ref-type="table-fn"}
  Ad vs insulin        ns        ns   ns                                                    ns                                                    ns                                                    ns
  p5-HT vs insulin     ns        ns   −0.368[\*\*](#tfn7-dmso-2-203){ref-type="table-fn"}   −0.387[\*\*](#tfn7-dmso-2-203){ref-type="table-fn"}   −0.359[\*\*](#tfn7-dmso-2-203){ref-type="table-fn"}   −0.371[\*\*](#tfn7-dmso-2-203){ref-type="table-fn"}
  NA vs glucagon       ns        ns   −0.318[\*](#tfn6-dmso-2-203){ref-type="table-fn"}     −0.409[\*\*](#tfn7-dmso-2-203){ref-type="table-fn"}   −0.396[\*\*](#tfn7-dmso-2-203){ref-type="table-fn"}   −0.402[\*\*](#tfn7-dmso-2-203){ref-type="table-fn"}
  DA vs glucagon       ns        ns   −0.297[\*](#tfn6-dmso-2-203){ref-type="table-fn"}     −0.346[\*](#tfn6-dmso-2-203){ref-type="table-fn"}     −0.401[\*\*](#tfn7-dmso-2-203){ref-type="table-fn"}   −0.411[\*\*](#tfn7-dmso-2-203){ref-type="table-fn"}
  Ad vs glucagon       ns        ns   ns                                                    ns                                                    ns                                                    ns
  P5-HT vs glucagon    ns        ns   ns                                                    0.363[\*](#tfn6-dmso-2-203){ref-type="table-fn"}      0.402[\*\*](#tfn7-dmso-2-203){ref-type="table-fn"}    0.416[\*\*](#tfn7-dmso-2-203){ref-type="table-fn"}
  NA vs HR             ns        ns   ns                                                    ns                                                    ns                                                    ns
  Ad vs HR             ns        ns   ns                                                    ns                                                    ns                                                    ns
  DA vs HR             ns        ns   ns                                                    ns                                                    ns                                                    ns
  NA/Ad vs SBP         ns        ns   ns                                                    ns                                                    ns                                                    ns
  NA/Ad vs DBP         ns        ns   0.232[\*](#tfn6-dmso-2-203){ref-type="table-fn"}      0.229[\*](#tfn6-dmso-2-203){ref-type="table-fn"}      0.239[\*](#tfn6-dmso-2-203){ref-type="table-fn"}      0.241[\*](#tfn6-dmso-2-203){ref-type="table-fn"}
  DA vs SBP            ns        ns   ns                                                    ns                                                    ns                                                    ns
  DA vs DBP            ns        ns   −0.218[\*](#tfn6-dmso-2-203){ref-type="table-fn"}     −0.222[\*](#tfn6-dmso-2-203){ref-type="table-fn"}     −0.219[\*](#tfn6-dmso-2-203){ref-type="table-fn"}     −0.231[\*](#tfn6-dmso-2-203){ref-type="table-fn"}

**Notes:** Levels of significance,

*P \<* 0.05;

*P \<* 0.01.

**Abbreviations:** NA, noradrenaline; Ad, adrenaline; DA, dopamine; p5-HT, platelet serotonin; f5-HT, plasma serotonin; HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure.

###### 

Changes in SBP, DBP, and HR induced in 15 normal voluntary healthy humans (eight males and seven females) when one OGTT plus placebo and one OGTT plus amantadine tests were carried out two weeks apart

                   OGTT + placebo test   OGTT + amantadine test                                         
  ---------------- --------------------- ---------------------------------------------------- --------- ------------------------------------------------------
  HR (beats/min)   71 ± 5                66 ± 7[\*](#tfn10-dmso-2-203){ref-type="table-fn"}   73 ± 7    65 ± 8[\*\*](#tfn11-dmso-2-203){ref-type="table-fn"}
  SBP (mm Hg)      127 ± 8               122 ± 3                                              127 ± 8   124 ± 7
  DBP (mm Hg)      73 ± 5                76 ± 4[\*](#tfn10-dmso-2-203){ref-type="table-fn"}   71 ± 6    88 ± 4[\*\*](#tfn11-dmso-2-203){ref-type="table-fn"}

**Notes:** Results are expressed as mean ± SEM.

*P* \< 0.05;

*P* \< 0.01 (versus 0 min value).

**Abbreviations:** DBP, diastolic blood pressure; HR, heart rate; OGTT, oral glucose tolerance test; SBP, systolic blood pressure; SEM, standard error of mean.
